Healthcare
Vera Therapeutics, Inc.(VERA)
Live Price
Offline$35.09
+0.23% today
1Y Change
+67.83%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $2.52B
- Revenue Growth
- 0.0%
- EPS Growth
- -69.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vera Therapeutics, Inc. (VERA) is a Healthcare stock with a market cap of $2.52B and listed on NASDAQ. The stock last traded around $35.09 and up 67.8% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -69.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -69.5%, free cash flow -78.2% with operating margin 0.0% and ROIC -46.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VERA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -69.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +6.0% | +6.3% | -9.4% |
2026 Feb 26, 2026 | -3.7% | -3.7% | -8.3% | -4.9% |
2025 Nov 5, 2025 | -5.0% | +4.6% | +29.0% | +76.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VERA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VERA Max Drawdown
-43.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VERA and SPY.
Company Overview
Vera Therapeutics, Inc.
NASDAQ Global Market
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
- Leadership
- Gary Barrera
- IPO Date
- May 14, 2021
- Employees
- 152
- Street Address
- 8000 Marina Boulevard
- Mailing
- Brisbane, CA, 94005
- Region
- Brisbane, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 770 0077
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.7
Growth
- Revenue
- 0.0%
- EPS
- -69.5%
- Free Cash Flow
- -78.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -59.7%
- ROIC
- -46.3%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 13.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.